High discontinuation rates highlight the importance of patient support programs to maximize the value of GLP-1 therapies

cover image Clinical insights and competitive intelligence on anticipated drugs in development Prime Therapeutics /quarterly-drug-pipeline-july-2024 About Prime Therapeutics Prime Therapeutics...

Ben Urick, senior director of health outcomes, and Landon Marshall, health outcomes research principal, share more about their educational session and research poster on GLP-1s

Update by Eagan-based Prime Therapeutics finds more patients quitting the popular weight-loss medications because of cost, access or short-term success

A Prime Therapeutics analysis of real-world data has found that medical costs for patients taking GLP-1 drugs for obesity had increased by about $1,338 per member, compared with a matched control...

Dec. 28, 2024: cosibelimab Checkpoint Therapeutics resubmitted an application for its anti-programmed death ligand-1 (PD-L1) antibody, cosibelimab, for the treatment for adults with metastatic or...

In this second of a two-part episode of the Pharmacy Friends podcast, industry experts discuss clinical evidence, drug information and appropriate patient selection for GLP-1 use

cover image Clinical insights and competitive intelligence on anticipated drugs in development Prime Therapeutics /quarterly-drug-pipeline-april-2024 About Prime Therapeutics Prime Therapeutics...

cover image Clinical insights and competitive intelligence on anticipated drugs in development Prime Therapeutics /quarterly-drug-pipeline-january-2024 About Prime Therapeutics Prime Therapeutics...

Publications Clinical Highlights: April 2025 Your monthly source for drug information highlights. Shortage updates The U.S. Government Accountability Office (GAO) has published a report on drug...

cover image Tracking the therapies shaping tomorrow’s care Prime Therapeutics /cell-gene-pipeline-outlook-november-2025 Prime Therapeutics’ Cell & Gene Pipeline Outlook is an industry report that...

As GLP-1 use expands, persistence remains a critical factor in realizing the therapies' full clinical potential

Event on Sept. 11 in Washington D.C. will feature the latest information on using GLP-1s to tackle the obesity epidemic.

Prime Therapeutics researchers shared real-world insights at AMCP Nexus 2025 on GLP-1 utilization, treatment persistence and strategies to improve access to these high-demand therapies

Real-world, integrated data follows-up on previous insights, analytics.

PUBLICATIONS FDA Decisions Expected: August 2025 Your monthly synopsis of new drugs expected to hit the market All brand names are property of their respective owners. References Press release:...

Prime Therapeutics discusses the challenges health plans face in expanding access to GLP-1 therapies while managing rising costs

Real-world research highlights patient persistence as a critical factor in achieving the long-term benefits of GLP-1 therapies

Polaris is awaiting an FDA decision for pegargiminase, an arginine degrading enzyme, for the treatment of malignant pleural mesothelioma (MPM) with non-epithelioid histology. The FDA granted the...

Learn with Biosimilar Basics. Part 1 starts with an overview of biosimilar products, sharing what biosimilar drugs are and the difference vs generic drugs.

Prime/MRx remains at the forefront of GLP-1 research, presenting weight loss studies at this year’s annual meeting.

In the latest episode of the “Pharmacy Friends” podcast, hear from Prime Therapeutics experts about how the fast-moving pipeline is changing how patients, providers and payers prepare for...

Unlock high-touch outreach Help members and their prescribers make better decisions about medicines through this clinical intelligence hub that delivers actionable insights, flexible levels of data...

Studies include Prime’s GLP-1 obesity research, the impact of social determinants of health and more.

Pat Gleason, assistant vice president, health outcomes, and David Eckwright, senior director, clinical project and program management, share an overview of Prime’s data and insights slated for this...

Insights from Academy of Managed Care Pharmacy (AMCP) Nexus 2023

Jessica Johnson, clinical consultant, shares how the Special Investigations Unit at Prime helps identify cases of fraud

Drug Approvals Monthly Update: January 2024 Traditional New drugs 1/05/2024 Zelsuvmi™ (berdazimer): The FDA approved Zelsuvmi for the topical treatment of molluscum contagiosum (MC) in adult and...

Prime Therapeutics experts explore how health plans expand access to GLP-1 therapies while maintaining affordability, clinical oversight and long-term sustainability

Drug Approvals Monthly Update: February 2024 Specialty New drugs 2/16/2024 Amtagvi™ (lifileucel) The United States (U.S.) Food and Drug Administration (FDA) approved the first-in-class...

In the latest episode of the “Pharmacy Friends” podcast, hear more about what faster drug decisions could mean for evidence review, affordability assessment and implementation planning

Reversal in obesity rate syncs with rising usage of expensive GLP-1 medications, but whether the trend will continue in Minnesota is unclear.

Home News & Insights Research & publications Drug Approvals Drug Approvals Monthly Update: September 2024 1. ADvocate 1 and 2 trials: https://pubmed.ncbi.nlm.nih.gov/36920778/ 2. ADhere trial:...

Urick, senior principal health outcomes researcher, shares more about his Spotlight Session at the Academy of Managed Care Pharmacy (AMCP)’s Annual Meeting

Read Drug Approval Update Specialty New drugs 06/06/2024 Rytelo™ (imetelstat) The FDA approved the first-in-class oligonucleotide telomerase inhibitor, Rytelo, for the treatment of adults with low-...

Specialty New drugs 3/18/2024 Lenmeldy™ (atidarsagene autotemcel) Lenmeldy is an autologous hematopoietic stem cell-based gene therapy by Orchard Therapeutics, which was FDA approved for the...

As use of GLP-1 therapies grows, new data shed light on the challenges of sustaining treatment over time

Read Drug Approval Update Specialty New drugs 04/22/2024 Anktiva® (nogapendekin alfa inbakicept-pmln) The FDA approved Anktiva for use in combination with Bacillus Calmette-Guérin (BCG) for the...

Prime to present seven studies and receive the 2024 JMCP Award for Excellence